We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio SAN FRANCISCO — A fixed-dose combination ...
Guadecitabine did not meet the co-primary endpoints of complete response (CR) rate or overall survival (OS) in the ASTRAL-1 study Astex continues to focus on completing the phase 3 ASTRAL-2 and ASTRAL ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results